Alzamend Neuro, Inc.
ALZN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001677077
In the last 90 days, Alzamend Neuro, Inc. insiders filed 1 open-market purchase and 1 sale; 12 institutions reported holding it in 13F filings for Q2 2026, worth $3.26M in total; no superinvestor holds it.
13F holders, Q3 2021
Institutional positions in Alzamend Neuro, Inc. as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 17
- +6 vs. Q2 2021
- Shares held
- 645.0K
- +349.3K (+118.1%) vs. Q2 2021
- Total value
- $1.99M
- −$596.0K (−23.1%) vs. Q2 2021
- New holders
- 11
- 5 more added
- Sold out
- 5
- 1 more reduced
Compare with Q2 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ALZN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 12 | $3.26M |
| Q1 2026 | 13 | $723.1K |
| Q4 2025 | 13 | $447.2K |
| Q3 2025 | 11 | $351.3K |
| Q2 2025 | 7 | $6.36K |
| Q1 2025 | 11 | $59.9K |
| Q4 2024 | 17 | $131.7K |
| Q3 2024 | 12 | $71.2K |
| Q2 2024 | 16 | $150.5K |
| Q1 2024 | 13 | $386.8K |
| Q4 2023 | 16 | $334.7K |
| Q3 2023 | 27 | $1.49M |
| Q2 2023 | 24 | $3.13M |
| Q1 2023 | 26 | $2.64M |
| Q4 2022 | 33 | $3.98M |
| Q3 2022 | 17 | $9.41M |
| Q2 2022 | 21 | $2.70M |
| Q1 2022 | 22 | $4.01M |
| Q4 2021 | 20 | $1.66M |
| Q3 2021 | 17 | $1.99M |
| Q2 2021 | 11 | $2.58M |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2021
Shares, value and share of portfolio for each institution holding Alzamend Neuro, Inc.; share changes are against Q2 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Morgan Stanley | 326 | $1.00K | 0.00% | +67+25.9% | Added |
| Allworth Financial LP | 300 | $1.00K | 0.00% | +300 | New |
| JPMorgan Chase & Co | 871 | $3.00K | 0.00% | +871 | New |
| Harbor Investment Advisory, LLC | 815 | $3.00K | 0.00% | +815 | New |
| UBS Group AG | 2,717 | $8.00K | 0.00% | +26+1.0% | Added |
| Cutler Group LP | 5,000 | $15.0K | 0.00% | +5,000 | New |
| Group One Trading, L.P. | 6,710 | $21.0K | 0.00% | +6,710 | New |
| Warberg Asset Management LLC | 14,000 | $43.0K | 0.01% | +14,000 | New |
| Tower Research Capital LLC (TRC) | 26,541 | $82.0K | 0.00% | +24,496+1,197.8% | Added |
| Schonfeld Strategic Advisors LLC | 31,600 | $97.0K | 0.00% | +31,600 | New |
| Citadel Advisors LLC | 45,225 | $139.0K | 0.00% | +45,225 | New |
| Cubist Systematic Strategies, LLC | 46,669 | $144.0K | 0.00% | +22,997+97.1% | Added |
| Qube Research & Technologies Ltd | 50,852 | $157.0K | 0.00% | +50,852 | New |
| Jane Street Group, LLC | 54,396 | $168.0K | 0.00% | −79,329−59.3% | Reduced |
| Susquehanna International Group, LLP | 92,276 | $284.0K | 0.00% | +35,246+61.8% | Added |
| Sassicaia Capital Advisers LLC | 93,762 | $289.0K | 0.82% | +93,762 | New |
| Two Sigma Investments, LP | 172,913 | $533.0K | 0.00% | +172,913 | New |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −44,600−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −16,018−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −15,402−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −193−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −27−100.0% | Sold out |